Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Contributed by: GlobeNewswire

Tags

nilo series a seth

More Like This

Tiziana Life Sciences Appoints New Chief Executive Officer

Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases

PR Newswire associated0

Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar

Bionoxx to Highlight Innovative Strategy for Addressing Immune-Related Diseases at 2024 BIO International Conference

Tiziana Life Sciences to Present at the Bio International Convention

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs